Head to Head Review: SciSparc (NASDAQ:SPRC) versus Madrigal Pharmaceuticals (NASDAQ:MDGL)

Madrigal Pharmaceuticals (NASDAQ:MDGL) and SciSparc (NASDAQ:SPRC) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.

Profitability

This table compares Madrigal Pharmaceuticals and SciSparc’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-30.08%	-43.76%	-24.88%
SciSparc	N/A	N/A	N/A

Volatility and Risk

Madrigal Pharmaceuticals has a beta of -0.97, indicating that its stock price is 197% less volatile than the S&P 500. Comparatively, SciSparc has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Madrigal Pharmaceuticals and SciSparc, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1	3	12	1	2.76
SciSparc	1	0	0	0	1.00

Madrigal Pharmaceuticals presently has a consensus price target of $685.31, suggesting a potential upside of 55.34%. Given Madrigal Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Madrigal Pharmaceuticals is more favorable than SciSparc.

Institutional & Insider Ownership

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 21.5% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 1.5% of SciSparc shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Madrigal Pharmaceuticals and SciSparc”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40 million	10.56	-$288.28 million	($12.87)	-34.28
SciSparc	$1.31 million	1.41	-$6.28 million	N/A	N/A

SciSparc has lower revenue, but higher earnings than Madrigal Pharmaceuticals.

Summary

Madrigal Pharmaceuticals beats SciSparc on 8 of the 13 factors compared between the two stocks.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

About SciSparc

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.